Aspira Womens Health Inc (AWH)
3.30
+0.02
(+0.61%)
USD |
NASDAQ |
Apr 26, 16:00
3.30
0.00 (0.00%)
After-Hours: 18:11
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 40.74M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -37.52% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 3.326 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -0.9581 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.25% |
Profile
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery. |
URL | https://www.aspirawh.com |
Investor Relations URL | https://ir.aspirawh.com/ |
HQ State/Province | Texas |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery. |
URL | https://www.aspirawh.com |
Investor Relations URL | https://ir.aspirawh.com/ |
HQ State/Province | Texas |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |